This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
At the Eastern Section meeting of The Triological Society in Toronto, Canada, on January 27, 1989, Drs Guy Tropper and Andre Lamothe, Ottawa, Canada, presented a feasibility study to preoperatively determine the predictive assay of tumor cell sensitivity with the use of bleomycin. Recognizing that various host tumor and treatment factors determine prognosis, the authors felt it would be helpful to have some type of method to determine sensitivity for predicting chemotherapeutic and radiation therapy responses. Preexisting methods include chromogenic assays, subrenal capsule assays, tumor oxygenation, cellular damage, and DNA damage assays. Desirability of a technique would be cost effectiveness, quick results, and strong clinical correlation. This paper used a technique known as FADU, or fluorescence analysis of DNA unwinding. With the use of this method they quantitated DNA damage after exposure to different concentrations of a chemotherapeutic agent. They used samples from 35 head and neck squamous cell carcinomas
PARNES S. In Search of a Predictive Assay of Tumor Cell Sensitivity in Head and Neck Oncology. Arch Otolaryngol Head Neck Surg. 1989;115(8):906. doi:10.1001/archotol.1989.01860320016007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: